Follow us on:

Arix Bioscience a diversified portfolio and an IRR of 20% since inception (Analyst Interview)

Arix Bioscience plc (LON:ARIX) is the topic of conversation when Dr Martin Hall, Analyst at Hardman & Co joins DirectorsTalk. Martin explains how Arix differs from other investment vehicles, how it has performed well since it released its interim results, trading relative to the NAV, narrowing the discount, the risks involved and what to expect from the company looking forward.

Questions we ask Dr Martin Hall:

Q1: Can you tell us what Arix does and how it differs from other investment vehicles?
Q2: The shares of Arix Bioscience have performed well since it released its interim results for 2020. Can you say what has been behind this movement?
Q3: So, how are the shares trading relative to the NAV?
Q4: What do you think will make this discount narrow?
Q5: What are the risks?
Q6: What is coming up in the near future?

Arix Bioscience is a United Kingdom-based healthcare and life science company. The Company is a holding company that is focused on generating value from the development and commercialization of technologies and discoveries.

You might also enjoy reading Putting H&T Group’s pawnbroking business into a global perspective (VIDEO)

Find more news, interviews, share price & company profile here for:

Hardman & Co

Share this interview

Other Interviews

Duke Capital Equity raise and third-party capital update (Video) November 19, 2024
ICG Enterprise Trust Operating companies’ widening margins and strong EBITDA growth (VIDEO) November 12, 2024
Real Estate Credit Investments Understanding the Discount, Its Rise, and Future Prospects (VIDEO) November 1, 2024
NB Private Equity Partners, the Unique Value of Co-Investment in Private Equity (VIDEO) October 28, 2024
Apax Global Alpha 1H24 Deal activity rebounding (VIDEO) October 14, 2024
Chesnara plc 2024 interim results a steady performance (VIDEO) October 11, 2024
Surface Transforms Plc: Strategic Moves and Market Potential with Mike Foster September 3, 2024
H&T Group plc 1H24 results curates egg of good and bad (VIDEO) August 30, 2024
Putting H&T Group’s pawnbroking business into a global perspective (VIDEO) August 14, 2024
Arbuthnot Banking Group PLC 1H’24 results: multiple options to get the most from the franchise (VIDEO) August 6, 2024

More News

Surface Transforms Plc: Strategic Moves and Market Potential with Mike Foster September 3, 2024
Volta Finance What we can learn from the Report and Accounts (VIDEO) February 12, 2024
Real Estate Credit Investments – Actively managing the portfolio to the latest market opportunities (VIDEO) November 27, 2023
Structured products investing: Volta Finance in Hardman Q&A (LON:VTA) May 9, 2023
China investment opportunities: In-depth analysis of Fidelity China Special Situations (LON:FCSS) April 13, 2023
Fidelity European Trust outperforms peers for dividend income investing March 15, 2023
Real Estate Credit Investments portfolio yield has risen by a tenth in recent months (LON:RECI) December 5, 2022
Fidelity European Trust resilience pays dividends LON:FEV (VIDEO) December 2, 2022
Performance, prospects and risks analysed for Fidelity Asia investment trust (LON:FAS) November 21, 2022
Income investing stock Volta Finance cash flows at near-record levels (LON:VTA) October 13, 2022

Search

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.